Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
AUTOR(ES)
Marsili, I
RESUMO
Bordetella pertussis 165-9K/129G, which produces a nontoxic form of pertussis toxin (PT), was used to prepare a whole-cell diphtheria-tetanus-pertussis (DTP) vaccine. The in vivo potency and the serological response induced by this vaccine were comparable to those of the conventional DTP vaccine which contains active PT. The toxic activities induced by PT such as leukocytosis, histamine sensitivity, and potentiation of anaphylactic reactions, which are present in the conventional DTP vaccine, were absent in the new vaccine. These results suggest that the introduction of a whole-cell vaccine containing B. pertussis 165-9K/129G would induce the same immunity as the conventional vaccine and would avoid the administration of a harmful toxin to children.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=257606Documentos Relacionados
- Construction of Bordetella pertussis strains that overproduce genetically inactivated pertussis toxin.
- CHEMICAL STUDIES ON CELLULAR COMPONENTS OF BORDETELLA PERTUSSIS III. : Isolation of Highly Potent Toxin from Bordetella Pertussis
- Ornithine-Containing Lipid of Bordetella pertussis That Carries Hemagglutinating Activity
- Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis.
- Variation in the Bordetella pertussis Virulence Factors Pertussis Toxin and Pertactin in Vaccine Strains and Clinical Isolates in Finland